Retatrutide vs Semaglutide: 24.2% vs 15% and What Actually Separates Them

Retatrutide and semaglutide sit one generation apart. Semaglutide defined what a GLP-1 medicine could do for body weight. Retatrutide, still in clinical development, reported numbers in Phase 2 that no single-receptor compound has matched. ^[1] This is an evidence-first comparison of the two, written for research and educational purposes. Everything below reports what the published literature describes; none of it is medical advice, and retatrutide is not approved for human use.

Retatrutide vs semaglutide at a glance

The table frames the whole comparison. Semaglutide is the known quantity with regulatory approval and a large safety record. Retatrutide is the higher-ceiling compound whose defining trial result outran the previous class by roughly ten percentage points of mean weight loss. ^{[1] [3]}

The headline difference: one receptor versus three

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which slows gastric emptying and signals satiety, so appetite falls and intake drops. That single mechanism, delivered at a once-weekly dose, is enough to produce the roughly 15% mean loss seen in STEP 1. ^[3]

Retatrutide activates three receptors with one molecule: GLP-1, GIP, and glucagon. ^[2] The GLP-1 and GIP arms drive appetite suppression, similar in spirit to what semaglutide and tirzepatide do. The glucagon arm is the addition that separates it. Glucagon-receptor activation raises energy expenditure and promotes hepatic fat mobilization, so retatrutide works on both sides of the energy-balance equation, intake and output, rather than intake alone. ^[2] That is the mechanistic reason its trial numbers sit above the single- and dual-agonist classes. For the full mechanism, see how the triple-agonist mechanism works.

How much weight each produced in trials

The two compounds have never been compared in the same trial, so the honest comparison is trial-to-trial, with the caveat that trial populations and durations differ.

Two things matter beyond the top-line percentages. First, retatrutide reached its 24.2% in a shorter window (48 weeks versus 68) and without a clear plateau, which suggests the endpoint figure may understate its ceiling. ^[1] Second, glycemic effects were comparable: retatrutide and semaglutide produced HbA1c reductions in a similar range in their diabetes cohorts, so the large divergence is specifically in weight, driven by the glucagon arm, not in glucose control. For the deeper single-compound picture, see the complete retatrutide guide and semaglutide's own guide.

Dosing and titration, side by side

Both are once-weekly subcutaneous compounds, and both rely on stepwise dose escalation to manage tolerability, but the dose scales are an order of magnitude apart.

The titration logic is identical: start low, climb slowly, let the gut adapt. The practical difference is that semaglutide has a fixed, well-characterized escalation schedule from its label, while retatrutide's schedule comes from the clinical-trial protocols rather than an approved regimen.

Side effects: how they compare

Both compounds are dominated by gastrointestinal effects. Nausea, diarrhea, and constipation are the common ones, they are dose-dependent, and they concentrate during the escalation phase rather than at steady state. ^{[1] [3]} This is a class characteristic of GLP-1 receptor agonism, so it shows up for both.

Two differences are worth naming. Retatrutide reported a skin-sensation effect (dysesthesia) at its highest doses that is not a typical semaglutide finding. ^[1] On the other side, semaglutide carries a far larger real-world safety record simply because it has been prescribed to millions of people over several years, whereas retatrutide's safety profile is still defined by trial populations. For a fuller treatment, see retatrutide's side effects covered in the main guide.

Timeline: how fast each one works

The onset pattern is similar. Appetite effects appear early, within the first weeks, while the meaningful weight change accrues over months as the dose escalates and steady state is reached. Both have roughly weekly half-lives (retatrutide near 6 days, semaglutide near 7), so both reach steady state over about four to five weeks of consistent weekly dosing and clear the system over a similar window after the last dose. The difference is not speed of onset but the height of the eventual plateau, which is where retatrutide's mechanism pulls ahead. ^[1]

Access: which one is easier to obtain

This is where the two diverge most sharply, and it has nothing to do with pharmacology.

Semaglutide is approved and widely available through prescription, and it exists in a large compounded market as well. Retatrutide is investigational. It is not approved for human use and is supplied only as a research compound, which means sourcing quality is the entire game: a batch-matched certificate of analysis, identity by mass spectrometry, a measured purity figure, and ideally independent third-party testing rather than only a vendor's own numbers. If you are evaluating a research supplier, how we vet a new manufacturer walks through exactly what to check.

Which one fits your research

Semaglutide is the reference standard: approved, characterized, and backed by years of data, which makes it the conservative choice when an established, well-documented GLP-1 is what a protocol calls for. Retatrutide is the frontier compound: a higher efficacy ceiling from a genuinely different three-receptor mechanism, at the cost of being investigational with a shorter safety record. For where each sits against tirzepatide as well, see the three-way comparison and retatrutide versus tirzepatide.

For research and educational purposes only. Not medical advice. These compounds are not approved for human use.